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The failure of several Phase II/III clinical trials in Alzheimer’s disease (AD) with drugs targeting 𝛽-amyloid accumulation
in the brain fuelled an increasing interest in alternative treatments against tau pathology, including approaches targeting tau
phosphatases/kinases, active and passive immunization, and anti-tau aggregation. The most advanced tau aggregation inhibitor
(TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form
(MT+). MT chloride (methylene blue) was investigated in a 24-week Phase II clinical trial in 321 patients with mild to moderate AD
that failed to show significant positive effects in mild AD patients, although long-term observations (50 weeks) and biomarker
studies suggested possible benefit. The dose of 138mg/day showed potential benefits on cognitive performance of moderately
affected AD patients and cerebral blood flow in mildly affected patients. Further clinical evidence will come from the large ongoing
Phase III trials for the treatment of AD and the behavioral variant of frontotemporal dementia on a new form of this TAI, more
bioavailable and less toxic at higher doses, called TRx0237. More recently, inhibitors of tau acetylation are being actively pursued
based on impressive results in animal studies obtained by salsalate, a clinically used derivative of salicylic acid.
1. Introduction
The2015 figures suggested that Alzheimer’s disease (AD)may
affect over 5.3 million people in the USA [1]. By 2050, the
number of new cases of AD per year is expected to grow,
resulting in nearly 1 million new cases per year, and the
estimated prevalence is expected to range from 11 million
to 16 million [1]. In the last three decades, notwithstanding
considerable advances in the AD neurobiology and medic-
inal chemistry, no disease-modifying treatments have been
introduced for this devastating and progressive neurode-
generative disease [2]. The neuropathological hallmarks of
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AD are intracellular neurofibrillary tangles (NFTs) composed
of paired helical filaments (PHFs) and straight filaments
(SFs)mainly constituted of hyperphosphorylated tau protein,
a microtubule associated protein (MAP), neuropil threads
(NTs), dystrophic neurites, and extracellular deposits of 𝛽-
amyloid (A𝛽) as the major component of senile plaques
(SPs) in the brain. These neuropathological hallmarks of
AD strongly influenced recent therapeutic approaches, with
a large portion of the many therapeutic approaches under
development for AD treatment directed against the produc-
tion and accumulation of A𝛽 [3]. However, several drugs
targeting A𝛽 with different mechanisms of action have failed
to demonstrate efficacy in randomized clinical trials or
their development has been halted [4, 5]. For the amyloid-
based approach, passive anti-A𝛽 immunization is the most
advanced strategy for treating AD, and solanezumab, a
monoclonal antibody directed at the mid-region of A𝛽,
also failed but suggested some beneficial cognitive effects
in mildly affected patients [4]. A Phase III study with a
planned size of 2100 mild AD patients is ongoing to confirm
these potential benefits. Solanezumab is also being tested in
a prevention study in asymptomatic older subjects, who have
positive positron emission tomography (PET) scans for brain
amyloid deposits [6]. Two other monoclonal antibodies,
gantenerumab, which preferentially binds to fibrillar A𝛽, and
crenezumab,which preferentially binds to soluble, oligomeric
and fibrillar A𝛽 deposits, are being tested in secondary
prevention trials in presymptomatic subjects with autosomal
dominant AD mutations [4, 6]. These ongoing secondary
prevention trials will tell us if A𝛽 really plays a crucial role
in the pathophysiology of AD. In fact, notwithstanding the
preeminence assigned to A𝛽, one crucial point was that large
numbers of amyloid SPs can occur in the course of normal
ageing without any evidence of clinical dementia. Given the
repeated failures of trials targeting the A𝛽 pathway in mild or
moderate AD [4], there is increasing interest in the possibility
that tau-targeted compounds could have therapeutic utility
in AD, particularly tau aggregation inhibitors (TAIs) [5, 7,
8]. The aim of this paper was to provide a comprehensive
review of tau-directed drugs for the treatment of AD, with
a particular focus on TAIs and the most clinically advanced
of these compounds, that is, leucomethylthioninium (LMT,
leucomethylene blue (MB), LMTX, TRx0237, TauRx Ther-
apeutics Ltd., Republic of Singapore), a second-generation
TAI for the AD treatment. TRx0237 shares the same active
ingredient and mode of action of another first-generation
TAI, that is, methylthioninium (MT, Rember, TRx-0014,
TauRx Therapeutics Ltd., Republic of Singapore), of which
is the reduced form, designed to have improved bioavail-
ability and tolerability. The chloride salt of oxidized MT+ is
methylthioninium chloride (MTC or MB).
2. Pathophysiology of Tau Protein in
Alzheimer’s Disease
Among pathological hallmarks of AD, the intracellular NFTs
contain two aggregated tau species, hyperphosphorylated
PHFs ofMAP tau (or tau) and SFs. Tau is a 50–75 kDa protein
with six different splice variants, referred to as 0N3R, 1N3R,
2N3R, 0N4R, 1N4R, and 2N4R [9, 10]. A short segment of tau
protein, referred to as the PHF core, from the repeat region
of the molecule is an integral structural constituent of the
PHF [11]. Abnormal phosphorylation/hyperphosphorylation
occurs in tau protein in AD, beginning to pair up with other
threads of tau into PHFs and tangle together, resulting in
the movement of tau proteins from axons to the somato-
dendritic compartment of neurons, causing disintegration
of microtubules, collapse of neuron’s transport system, and
formation of extremely insoluble aggregates. These changes
are presumed to disrupt neuronal communication and lead
to cell death [12]. NFTs are generated intracellularly, but
when neurons die, the only NFTs remaining are “ghost
tangles” which are localized outside of cells where the host
neuron has died. Ghost tangles are a common finding in AD
patients which can occur also in preclinical stages [13]. In
this preclinical phase of AD, the earliest involved neurons
are those in the locus coeruleus, and the subcortical tau
lesions then reach the noradrenergic coeruleus neurons of
the contralateral brainstem, so that the pathological pro-
cess becomes symmetrical soon after its onset. Thereafter,
additional nuclei with diffuse cortical projections become
involved [14]. H. Braak and E. Braak demonstrated that
appearance of tau pathology in AD occurs in a characteristic
pattern of development in six stages, with NFTs and NTs
appearing first in the entorhinal cortex (stages I and II),
followed by hippocampal (stages III and IV), and neocortical
areas (stages V and VI) [13–15]. A corresponding staging for
A𝛽 deposition was compared with tau staging, with three
levels of increasing A𝛽 deposits (stages A–C), in a large
autopsy case series of subjects between the ages of 25 and
95 years [16]. These findings suggested that tau aggregation
precedes A𝛽 deposits by about three decades [16], confirming
earlier reports showing the same pattern [17, 18].
The exact mechanisms by which tau protein becomes
a nonfunctional entity are under debate. Tau pathology in
AD is principally characterized by abnormal phosphoryla-
tion/hyperphosphorylation of tau proteins, but also prote-
olytic cleavage (truncation), glycosylation, nitration, acetyla-
tion, O-GlcNAcylation, ubiquitination, and other abnormal
posttranslational modifications are responsible for altered
tau structure in this devastating neurodegenerative disease
[11, 19–25]. All these molecular events are associated with the
formation of PHFs and the appearance of NFTs. In particular,
abnormal phosphorylation/hyperphosphorylation, acetyla-
tion, and truncation are further supported as pathological
events by in vitro experiments [22, 26–29], demonstrat-
ing that these modifications increase fibrillization of tau
and induce cell toxicity. Truncation/proteolytic cleavage of
tau protein, as an alternative mechanism involving in the
abnormal aggregation of tau, was proposed after extensive
biochemical analysis of the PHF core [11, 21], with prion-like
properties in vitro. Until today, identification of the enzyme
that produces this abnormal posttranslational modification
is uncertain. Caspases, which are apparently elevated in AD
brain [30, 31], are likely involved in the proteolytic processing
of tau protein.The repeat domain of tau is able to catalyse and
propagate the conversion of normal soluble tau into accumu-
lations of the aggregated and truncated oligomeric forms [5].
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In fact, hyperphosphorylated tau proteins bind together and
form oligomeric tau, from dimers to octamers [32]. Both
hyperphosphorylated tau by itself and oligomeric tau are
involved in synaptic loss, as observed in the wild-type human
tau transgenicmouse [25, 33]. Indeed, protein aggregatesmay
in general be protective in neurodegeneration by sequestering
dispersed small aggregates, oligomers, or misfolded proteins,
minimizing their toxicity and eventually facilitating their
clearance by proteasomal activity or autophagy [34–36], a
model that remains to be validated with respect to tau protein
and AD [37]. However, proteolytically stable tau oligomers
are able to propagate between neurons and initiate the
cascade of self-propagating misfolded proteins from neuron
to neuron [38, 39]. Therefore, the tau pathology of AD can
be understood as a self-propagating “prionosis,” reflecting
degrees of spread of tau that may form an endopathogenic
species transmitting neurodegeneration from one cell to the
next throughout the brain [40]. On this basis, vaccination of
mice in experimental models of tauopathy and synucleinopa-
thy, involving intracellular proteins, has showed promising
findings [41, 42].
3. Tau-Based Drugs for the Treatment of
Alzheimer’s Disease
In AD, given the confirmed link existing between NFT
topography and clinical phenotype [43], and the abnormal
posttranslational modifications of tau protein linked to the
disease [11, 19–25], therapies targeting NFTs and tau pro-
tein may have potential application as drug targets against
neurodegeneration [44–46], although their development has
lagged behind drugs targeting A𝛽. At present, therapies
targeting tau aim to reduce, stabilize, or prevent aggrega-
tion or hyperphosphorylation of the protein [44–46]. In
particular, several therapeutic approaches with a disease-
modifying potential have been suggested: (1) inhibition of tau
phosphorylation (with the inhibition of tau kinases or the
activation of tau phosphatases); (2) increase of microtubule
stabilization; (3) increase of tau clearance and (4) inhibition
of tau aggregation. Some of these approaches have actually
reached the clinic [7].
Abnormal phosphorylation of tau protein may play a
critical role in the pathogenesis ofNFTdegeneration,with the
balance between kinases and phosphatases disturbed in AD,
leading tau protein to become detached from microtubules,
secondarily to aggregate. There is approximately a four- to
fivefold higher level of total tau in AD brain compared to
that of age-matched healthy brains and this increase is all in
the form of the abnormally hyperphosphorylated tau [47]. In
AD, the abnormal phosphorylation of tau could be, but not
mutually exclusive, the result of upregulation of tau kinases
or downregulation of tau phosphatases [9]. In this scenario,
a tau-based therapeutic approach would target a kinase
particularly responsible for a pattern of phosphorylation
causing reduced microtubule stability.
Tau protein kinases are grouped into three main classes:
proline-directed protein kinases (PDPK), protein kinases
non-PDPK, and tyrosine protein kinases (TPK) [48]. Among
these enzymes, the kinases with the most important role
in phosphorylation of tau protein in the brain include
glycogen synthase kinase 3𝛽 (GSK-3𝛽), cyclin-dependent
kinase 5 (CDK5), cAMP-dependent protein kinase (PKA),
and calcium/calmodulin-dependent kinase II (CaMKII) [49].
GSK-3𝛽 may play a major role in regulating tau phospho-
rylation in both physiological and pathological conditions.
Interactions between GSK-3𝛽 and CDK5 also exist and will
require further evaluation to optimize treatments aimed at
these kinases [50, 51]. Despite the challenges faced by this
approach with respect to toxicity and specificity, a number
of efforts are underway to develop kinase inhibitors. In
particular, in addition to a series of compounds directed at
kinases of the PDPK and non-PDPK groups in preclinical
development that should be tested in in vivo studies [48, 52],
one GSK-3𝛽 inhibitor, tideglusib (NP031112, NP-12, Nypta,
Zentylor, Noscira SA,Madrid, Spain), a drugwhich belongs
to the thiadiazolidinone family, was in clinical trials for AD
and progressive supranuclear palsy (PSP) [5, 7, 53]. In a
previous Phase IIa trial, tideglusib was orally administered
at escalated doses of 400 up to 1000mg/day for 20 weeks
to 30 patients with mild to moderate AD and the active
group showed positive trends in four out of five clinical scales
and had significantly better response on the Mini-Mental
State Examination (MMSE), with asymptomatic elevation of
transaminases, reversed with withdrawal of the drug [54].
The ARGO study, a subsequent six-month, Phase IIb trial,
was conducted to assess safety and efficacy of tideglusib in
mild to moderate AD patients with the 15-item modified
version of the Alzheimer’s Disease Assessment Scale (ADAS-
cog
15
) as the principal outcomemeasure.However, the results
demonstrated no statistically significant findings, although
the drug was well tolerated with diarrhea and asymptomatic
transaminase elevations as the only side effects [55]. There
are no current FDA approved trials ongoing for treating
AD with tideglusib. Activation of phosphatases, in particular
protein phosphatase 2A (PP2A), has also been proposed as a
possible alternative strategy to kinase inhibition for reducing
tau phosphorylation [44, 49, 56]. Multiple PP2As exist and
inhibition of these phosphatases results in hyperphosphory-
lation of tau, formation of NFT-like structures, and memory
impairment in animal models [57–59]. Drugs increasing the
activity of PP2As, probably through the endogenous proteins
that inhibit their activity, have the therapeutic potential
for treating AD [60, 61], but no clinical trials with PP2A
activators have been started yet.
Among tau-based anti-AD drugs, several microtubule-
stabilizing agents have been tested and the studies carried out
have provided proof of concept that compoundswith the abil-
ity to stabilize microtubules may have therapeutic potential
for the treatment of AD and other neurodegenerative diseases
[62], given that tau detachment from microtubules results in
loss of its normal microtubule-stabilizing function, probably
leading to axonal transport impairment and eventually to
synaptic dysfunction. Some antimitotic compounds such
as paclitaxel (Taxol, Bristol-Myers Squibb Company, New
York City, USA), epothilone D (Epo D, BMS-241027, Bristol-
Myers Squibb Company, New York City, USA), or TPI-
287 (Cortice Biosciences, New York City, USA, formerly
Archer Biosciences) have been used in tau transgenic animals
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for their microtubule-stabilizing activity [7, 63, 64], but at
present, these compounds did not reach the clinic due to toxic
side effects (paclitaxel) or have been discontinued for AD
(epothiloneD) or are in Phase I of clinical development (TPI-
287) formild tomoderateAD [65] (Table 1) and primary four-
repeat tauopathy, corticobasal degeneration (CBD), CBD
syndrome, and PSP [66]. In particular, in a preventative
study, epothilone D was administered weekly for 3 months
to young PS19 tau Tg mice that initially lacked significant
tau pathology, preventing the axonal microtubule loss and
dystrophy, as well as spatial learning deficits, that manifested
as these mice developed forebrain tau pathology with age
[67]. In another preclinical study, in both young and old
animals of the PS19 tauopathy model, in which tau pathology
is developing or well established, respectively, epothilone
D reversed behavioral and cognitive deficits, cleared tau
pathology, and increased hippocampal neuronal integrity
[63]. Based on these encouraging findings, in February 2012,
Bristol-Myers Squibb started a Phase I trial to evaluate the
tolerability and pharmacology of epothilone D in 40 patients
withmild AD, comparing 0.003, 0.01, and 0.03mg/kg infused
once a week for nine weeks to placebo [68]. The study ended
in October 2013, but evaluation of epothilone D for AD was
subsequently discontinued.
Among microtubule-stabilizing agents, davunetide
(NAPVSIPQ,NAP,AL-108, AllonTherapeutics Inc., Vancouver,
Canada, Paladin Labs Inc., Montreal, Canada), an eight-
amino acid peptide (with NAP representing the first three
amino acids in the peptide) derived from the activity-
dependent neuroprotective protein (ADNP), has demon-
strated the potential to decrease tau phosphorylation and A𝛽
levels in animal models [69]. In particular, NAP stabilizes
microtubules and reduces hyperphosphorylated tau levels
[70] and in a mouse model of amyotrophic lateral sclerosis
(ALS) it protected against impairments in axonal transport
[71], suggesting that reduction of tau hyperphosphorylation,
stabilization of microtubules, and neuroprotective effects
may be beneficial to prevent disease progression. An
intranasal formulation of davunetide was tested in Phase II
clinical trials for both mild cognitive impairment (MCI) and
PSP, given that intranasally administered NAP treatment can
cross the blood-brain barrier (BBB). In 2007-2008, the Phase
II trial in 144 subjects with MCI demonstrated a statistically
significant improvement in memory performance compared
with placebo at eight weeks and 16 weeks, but not 12 weeks,
with well-tolerable side effects [72]. However, the results
of the Phase II/III trial in the pure tauopathy PSP were
unimpressive [73], suggesting intervention at early stages of
the disease [62].This result halted, for the time being, clinical
development of davunetide. This decision also prompted a
halt to recruitment into an ongoing safety and biomarker
trial, begun in 2010, of davunetide in frontotemporal lobar
degeneration (FTLD) with predicted tau pathology, CBD
syndrome, or PSP [73]. An intravenous formulation of
davunetide also exists (AL-208) and this version of the drug
was tested between 2006 and 2008 in a Phase II trial of the
safety and efficacy of a single 300 mg IV dose on cognitive
impairment following coronary artery bypass surgery [74],
with no published results.
Recent efforts to develop safe and efficacious anti-A𝛽
immunotherapy usingA𝛽 peptide as an immunogen in active
vaccination approaches or anti-A𝛽 antibodies for passive vac-
cination may be translated to the development of a tau-based
immunotherapy [45]. Clearance of extracellular misfolded
tau protein may prevent the transmission and spreading of
tau pathology throughout the brain. Active immunization
of wild-type mice with recombinant unphosphorylated full-
length human tau protein led to encephalomyelitis with
neurological and behavioral deficits, axonal damage, and
inflammation [75], suggesting a neurotoxic potential of tau
immunization. However, the feasibility of this approach was
later demonstrated with a 30-amino acid tau phosphopeptide
spanning amino acids 379–408, including phospho-Ser at
positions 396 and 404, in two different transgenic mouse
models of disease, the JNPL3 (P301L) and htau/presenilin 1
(PS1) lines [41, 76], which both resulted in a specific anti-
body response, reduced tau burden, and attenuation in the
severity of behavioral and cognitive phenotypes [77]. Among
active vaccines in clinical trials, AADvac1 (Axon peptide 108
conjugated to KLH, Axon Neuroscience, Bratislava, Slovak
Republic) was the first anti-tau vaccine to enter clinical
trials and it is a synthetic peptide derived from amino acids
294 to 305 of the tau sequence, that is, KDNIKHVPGGGS,
coupled to keyhole limpet hemocyanin (KLH) through an
N-terminal cysteine, and administered with an Alhydrogel
alum adjuvant. In transgenic tau rats, the vaccine reduced tau
pathology and associated behavioral deficits [78]. AADvac1
was designed to target misfolded tau in AD, and its safety,
tolerability, and efficacy have been evaluated in a first-in-man
Phase I clinical trial conducted in three centers in Austria on
30 patients with mild to moderate AD, completed on March
2015 [79] (Table 1). Two withdrew due to adverse events, of
which one (a viral infection followed by epileptic seizure)
was considered to be possibly related to the vaccine. Unfor-
tunately, the double-blind, placebo-controlled portion of the
study lasted only 12 weeks and the study evaluated only one
dose of the vaccine (40 𝜇g). No data on cerebrospinal fluid
(CSF) biomarkers were reported. These deficiencies limit the
interpretability of the results both in terms of safety and
on target engagement. The subsequent 12-week open label
portion of the study is of limited information [80]. Patients
completing this 24-week study had the option to enter a
further 18-month open label extension (FUNDAMANT) [81]
(Table 1). A separate 24-month Phase II study in 185 patients
with mild AD and a magnetic resonance imaging (MRI)
consistent with this diagnosis was planned to start on March
2016. This study will compare 8 subcutaneous injections of
40 𝜇g of AADvac1 with the adjuvant aluminum hydroxide
to placebo. The primary outcome will be safety, and sec-
ondary outcomes will include cognitive and clinical batteries
as well a measure of immunogenicity. Fluorodeoxyglucose
(FDG) PET, MRI volumetry, and CSF biochemistry were
set as exploratory outcomes (ClinicalTrials.gov Identifier:
NCT02579252, ADAMANT) [82] (Table 1).
The vaccineACI-35 (AC ImmuneAG, Lausanne, Switzer-
land and Janssen Pharmaceuticals, Beerse, Belgium) is a
liposomal-based 16-amino acid tetrapalmitoylated phospho-
tau peptide with specific amino acid areas incorporated into
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TRx0237 125mg tablets
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220 patients with behavioral
variant of FTD (2013–2016)
TRx0237 100mg tablet
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evaluate the long-term safety of
TRx0237 (2014–2017)
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given 200mg/day of TRx0237
administered twice daily.
Thereafter, dosing is flexible
(100mg/day to 300mg/day)









33 patients with mild to
moderate AD (2013–2015)
The purpose of the study is to
determine the highest dose of
TPI-287 that is safe and
tolerable when administered as
an intravenous infusion








30 patients with mild to
moderate AD (2013–2015)
Patients will receive 1 dose of
AADvac1 per month over 3
months, for a total of 3
administrations
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to observe patients who have
completed the Phase I trial of
AADvac1, for another 18
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Patients who have received 6
doses in the previous trial will
be given 1-2 booster doses of
AADvac1 (2 if their antibody
titers decline below those
achieved in the previous trial).
Patients who have received 3
doses in the previous trial will
be given another 3 doses and
then vaccinated with booster
doses as above
18-month follow-up








185 patients with mild AD
(2016–2019)
Patients will receive 6 doses of
AADvac1 in 4-week intervals
and then 2 individual booster
doses in 6-month intervals, for
a total of 8 doses







Patients with mild to moderate
AD (2013–2014)
This Phase I trial compared two
doses of ACI-35 to investigate
its safety, tolerability, and
immunogenicity













Phase I trial (active, not
recruiting)
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the vaccine including phosphorylated S396 and S404 residues
that also provides active immunization. It elicits a rapid
immune response against the immunogen in wild type and
transgenic JNPL3 (P301L) mice, resulting in a mild reduction
of hyperphosphorylated pathological tau and tau pathology
by immunohistochemical characterization and increased IgG
titers and motor function of vaccinated mice [83]. ACI-35
also demonstrated a good safety profile for human studies,
with no adverse inflammatory response [83]. Currently, a
Phase Ib trial is underway in mild to moderate AD to
assess safety profile alongwith secondary outcomes including
biomarkers, functional, and clinical change (Table 1), but
details are not available and this trial is not listed in Clini-
calTrials.gov or the World Health Organization’s clinical trial
registry.
For passive vaccination, anti-tau oligomer antibodiesmay
be ideal candidates for treating AD [84], similar to the ones
developed for A𝛽 [85], with exciting opportunities to validate
anti-tau oligomer immunotherapeutic approaches in animal
models. In the first program to demonstrate the efficacy of
tau-based immunotherapy, this approach has been tested by
injecting anti-phospho-tau antibody PHF1, which recognizes
the pS396/pS404 epitope, intraperitoneally to JNPL3 (P301L)
tau transgenic mice, with preliminary findings indicating
that treated animals showed decreased tau pathology and
functional impairment [86]. Similar effects were obtained
also with other antibodies against the pS396/pS404 epitope
[87, 88]. Several tau antibodies are currently in early clinical
development as therapies for AD and other tauopathies [45].
Among these antibodies, RG7345 (RO6926496, MAb86, F.
Hoffmann-La Roche Ltd., Basel, Switzerland) is a human
monoclonal antibody targeting a specific tau phosphorylated
epitope at site pS422, which is prominent in neuronal den-
drites [89, 90] and linked to the relocalization of tau protein
away from microtubules and toward the somatodendritic
compartment of the neuron [89]. Furthermore, in a triple
transgenic mouse model of AD, the passive administration
of the antibody demonstrated a reduced accumulation of
tau pathology with intracellular clearance of tau antibody
complexes [90]. In January 2015, a Phase I, single-ascending-
dose study in 48 healthy young men in the United Kingdom
started, comparing the safety and pharmacokinetic measures
of six different doses to placebo, all infused intravenously [91]
(Table 1). Finally, BMS-986168 (IPN007, Bristol-Myers Squibb
Company, New York City, USA), although not currently
approved for AD but only for PSP [92], is a humanized mon-
oclonal antibody directed toward extracellular, N-terminally
fragmented forms of tau (eTau), which were originally iso-
lated from familial AD patient-derived pluripotent stem cells.
A recent study demonstrated a correlation between eTau and
A𝛽 both in vitro and in two transgenic in vivo mice models,
with a reduction in A𝛽 that occurs when eTau is targeted with
an antibody [93]. Secreted forms of tauwere reported to cause
neuronal hyperactivity, which could, in turn, increase A𝛽
production, fueling a feed-forward cycle [93]. In December
2014, a Phase I, single-center, single-ascending-dose study
in 48 healthy volunteers in Texas started. This first human
trial will assess safety parameters for up to eight months after
administration of a single infusion of BMS-986168 [94].
4. Covalent and Noncovalent Tau
Aggregation Inhibitors for the Treatment of
Alzheimer’s Disease
Among several tau-directed approaches in AD, small molec-
ular weight compounds developed to inhibit formation of tau
oligomers and fibrils by blocking tau-tau aggregation have
already been tested in humans [5, 7, 95, 96]. In cell-based
and/or in vitro screening assays, several classes of agents
that may act to prevent tau aggregation have been identified,
including but not limited to polyphenols [80], porphyrins
[80], phenothiazines [97], benzothiazoles/cyanines [98, 99],
N-phenylamines [100], thioxothiazolidinones (rhodanines)
[101], phenylthiazole-hydrazides [102], anthraquinones [103],
and aminothienopyridazines (ATPZs) [104]. However, for
many TAIs there is a lack of evidence of efficacy in vivo
for inhibiting tau aggregation. Currently, TAIs fall into two
broad mechanistic classes, with the first class corresponding
to covalent TAIs, that is, agents that either covalently modify
tau directly or foster formation of covalent bonds within
or between tau proteins to yield aggregation-incompetent
products [95]. Covalent TAIs can attack any or all species
in an aggregation pathway but appear to be especially effi-
cacious modifiers of tau monomers [95]. Among covalent
TAIs, oleocanthal, a natural product aldehyde, reacts with
epsilon amino groups of lysine residues [105, 106], including
residues residing in the microtubule binding repeat region,
to form imines. In addition, other natural polyphenols are
covalent TAIs, such as oleuropein aglycone [107], abundant
in the extra virgin olive oil, or green tea-derived (−)-
epigallocatechin gallate (EGCG) [108]. Other redox-active
compounds, including the nonneuroleptic phenothiazine
MB, that is, MTC, can alsomodulate cysteine oxidation when
incubated in the absence of exogenous reducing agents [109].
High concentrations of reduced sulfhydryl groups in the form
of glutathione normally maintain a reducing intracellular
environment [110], and therefore compounds acting solely
through this mechanism could have low potency and efficacy
in vivo. In general, covalent mechanisms of tau aggregation
inhibition in AD are predicted to have low utility in vivo
[111]. However, dimethylfumarate, an electrophile capable of
reacting covalently with cysteine sulfhydryls, was approved
for oral treatment of multiple sclerosis [112], suggesting that
electrophilic compounds acting through covalent inhibitory
mechanisms can be useful therapeutic agents.
The second broad class of TAIs interacts with tau species
noncovalently, through multiple mechanisms, and with dif-
ferent structures [95, 113]. Among different mechanisms,
small molecules can interact directly but transiently with
natively unfolded tau protein monomer [95]. For example,
curcumin has been reported to increase the reconfiguration
rate (i.e., a rapid rate of interconversion between aggregation
competent and incompetent conformations) of 𝛼-synuclein,
such that occupancy of assembly competent conformations
is minimized [114]. Because tau aggregation is sensitive to
curcumin conjugates [115], this mechanism may be relevant
also for tau protein. Noncovalent TAIs also may act by block-
ing formation of steric zipper structures common to cross-
𝛽-sheet forming peptides. Short segments of amyloidogenic
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sequences have been crystallized in forms that exhibit similar
properties as their full-length counterparts [116]. Further-
more, tau filament formation can be inhibited by sequestering
tau in the form of stable off-aggregation pathway oligomers.
For example, phthalocyanine tetrasulfonate, a cyclic tetrapyr-
role, interacts directly with tau monomers to form SDS-
stable oligomers [117]. Similarly, in a study of 𝛼-synuclein
aggregation, polyphenol, phenothiazine, polyene macrolide,
porphyrin, and Congo red derivatives were found to stabi-
lize SDS- and Sarkosyl-insoluble oligomers [118]. SDS-stable
oligomers composed of full-length tau also rapidly form at
low micromolar concentrations in the presence of cyanine,
triarylmethine, rhodanine, and phenothiazine TAIs [80, 111].
Since tau can coaggregate with other proteins, including
microtubule associated proteins and alpha-synuclein [119],
TAIs may work through binding to these proteins. Indeed,
numerous polyphenols have been identified that inhibit
aggregation of a wide variety of amyloidogenic peptides
including tau and 𝛼-synuclein [113], but no studies with selec-
tive TAIs are currently available to support this hypothesis.
5. Tau Aggregation Inhibitors in Clinical
Development for the Treatment of
Alzheimer’s Disease: Preclinical Studies
of Methylthioninium and Derivatives
TAIs are divided into covalent and noncovalent molecules
depending on their way to interact with tau protein. The
chemical structure of noncovalent TAIs differs significantly in
terms of scaffold [95]. Structure-activity relationships (SARs)
were established within specific chemical series [120, 121].
Like common dyes, most TAIs absorb electromagnetic radia-
tion in the visible spectrum, a property linked to the property
of delocalizing 𝜋-electron distribution [122]. Ligand polar-
izability correlates with tau aggregation inhibitory potency
within specific chemical series of cyanine, phenothiazine,
arylmethine, and rhodanine derivatives [111]. MB or MTC
(Rember) is and old dye repurposed as medical treatment
of tau pathologies [123]. Chemically, MTC is a tricyclic
phenothiazine derivative [124] and exists in equilibrium
between reduced (LMT) and oxidized form (MT+). Under
physiological conditions, it is present as a cation (MT+) and
formulated as a chloride salt (commonly known as MB).
MTC may be reduced by nicotinamide adenine dinucleotide
phosphate (NADPH) or thioredoxin to give LMT (leuco-
MB), an uncharged colorless compound (methylene white).
MTC is excreted in the urine as a mixture of MTC, LMT,
anddemethylatedmetabolites, for example, azure B and azure
A [125]. MTC has been used to treat malaria [126], methe-
moglobinemia [123], and depression [127]. MTC efficiently
crosses the BBB [128] and selectively penetrates neurons
after systemic administration, particularly hippocampal cells
[129]. At present, MTC and its derivatives represent the most
advanced TAIs in clinical development for the treatment
of AD. MTC has been shown to interfere with the tau-tau
binding necessary for aggregation [97]. In a cell-based model
of inducible tau aggregation, the inhibitory constant of MTC
was found to be 123 nM [5]. Other studies reported quite
different in vitro inhibitory potency (IC
50
) varying from
1.9 𝜇M [80] to 3.5 𝜇M [99]. The estimated trough brain con-
centration of MT (Rember) and its active metabolites in the
human brain at the 138mg/day dose was 0.18 𝜇M [130]. This
value appears to be in the range of the in vitro IC
50
values for
dissolution of PHFs (0.16 𝜇M) and the calculated intracellular
Ki for TAI activity (0.12 𝜇M) [131] but not in the range of
IC
50
s of other in vitro [80] and cell-based [99] studies. In tau
transgenic mouse models, MT levels in the brain followed
a sigmoidal concentration-response relationship over a 10-
fold range (0.13–1.38 𝜇M) after oral administration of 5–
75mg/kg for 3–8 weeks [132]. Alternative mechanisms of
action have been proposed for MT [5] including inhibition
of microtubule assembly [104] that requires IC
50
of 50𝜇M
[5, 104]. However, the dose required to achieve inhibition
of microtubule assembly with MTC would be about 50 g
of MTC/day [5], exceeding the median lethal dose (LD
50
)
for MTC in several species. Similarly, it has been proposed
that MTCmay reduce endogenous production of tau protein
[133], but EC
50
for this effect is 10𝜇M, requiring a human
clinical dose of 9 g ofMTC/day, a dose that could not safely be
administered in humans. It has been also proposed thatMTC
could affect tau phosphorylation via inhibition of Hsp70
ATPase [134], but again EC
50
for this effect is 83𝜇M, with a
theoretical dose in humans of 75 g MTC/day.
Recent in vivo and in vitro studies have suggested that
MTC may reduce tau protein aggregates in AD through
proteasomal [135] and macroautophagic [136, 137] degra-
dation of the protein. Other potential effects of MTC are
oxidation of cysteine sulfhydryl groups in the tau repeat
domain preventing formation of disulphide bridges to keep
tau monomeric [138], acetylcholinesterase inhibition [139],
nitric oxide synthase inhibition [140], noradrenaline uptake
inhibition [141], glutamatergic inhibition [142], monoamine
oxidase B inhibition [143], guanylate cyclase inhibition [140],
and inhibition of the aggregation of A𝛽 peptides [80, 97,
144], stimulation of A𝛽 clearance [145], improvement of
brain metabolism [146–150], improvement of astrocyte cel-
lular respiration [151], improvement of brain mitochondrial
amyloid-binding alcohol dehydrogenase (ABAD) functions
[150], improvement of mitochondrial antioxidant properties
[152, 153], improvement of the Nrf2/antioxidant response
element (ARE) [154–156], antagonism of 𝛼7-nicotinic acetyl-
choline receptors [157], inhibition of 𝛽-secretase activity
[149], enhancement of mitochondrial oxidation [158], and
inhibition of monoamine oxidase A [143]. However, the
clinical relevance of these potential effects is doubtful. On
the other hand, there are only a few reports on the effect
of MTC on tau aggregation in vivo [135, 136, 159–161]. In
one study, MTC did not alter abnormal tau phosphorylation
and failed to inhibit tau-dependent neuronal cell toxicity in
zebrafish [159]. In another study, MTC treatment reduced
detergent-insoluble phosphorylated tau levels in the JNPL3
(P301L) tau transgenic mice [160]. Treatment of 3-month-
old rTg4510 mice for 12 weeks with oral MTC prevented
behavioral deficits and reduced soluble tau levels in the
brain [135]. JNPL3 (P301L) mice treated with MTC for 2
weeks showed reduced soluble tau levels without affecting
insoluble tau levels [136]. These studies indicate that MTC
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treatmentmay reduce soluble tau levels and prevent cognitive
decline when treatment begins at a time point before NFTs
are present in the brain [135]. A recent study suggested
that 6 weeks of oral treatment with MTC did not reverse
established NFT pathology in the rTg4510 mouse model of
tauopathy [161]. Some studies reported a generalized antiag-
gregation effect for MTC against aggregation-prone proteins,
such as prion protein [162], 𝛼-synuclein, and transactivation
response (TAR) DNA-binding protein of Mr 43 kDa (TDP-
43) [163, 164]. This further activity of MTC has potential
relevance for the treatment of ALS and FTLD [165].
6. Clinical Efficacy and Safety of
Methylthioninium and Derivatives
Adouble-blind, randomized, placebo-controlled study evalu-
ates the safety and explorative efficacy of MT (Rember) given
doses of 69mg, 138mg, and 228mg/day (equivalent to 30mg,
60mg, and 100mg MTC) for 24 weeks to 321 mild to mod-
erate AD patients who were not taking acetylcholinesterase
inhibitors (AChEIs) or memantine (ClinicalTrials.gov Iden-
tifier: NCT00515333) (Table 1). The primary efficacy out-
come of the study was the change in the ADAS-cog at
24 weeks relative to baseline. The effects of treatments on
regional cerebral blood flow (rCBF) decline were determined
in a subgroup of 135 patients using hexamethyl-propyl-
amine-oxime single photon emission computed tomography
(HMPAO-SPECT). At the end of the 24-week, double-blind,
placebo-controlled treatment period, patients had the option
to enter two consecutive open label extensions of 26 and
48 weeks, respectively [166]. At 24 weeks, there were not
significant differences between treatment groups compared
to placebo in any of the efficacy variables. Post hoc subgroup
analyses revealed that in moderately affected patients there
was significant treatment benefit of the intermediate dose
of 138mg/day compared to placebo on the ADAS-cog scale
(5.42 points, 𝑝 = 0.047). In mildly affected patients, there
was a significant beneficial effect of the 138mg/day compared
placebo on the all regions other than the left frontal lobe
(1.97%, 𝑝 < 0.001) [166].
A total of 111 patients completed the first open label
extension of 26 weeks (ClinicalTrials.gov Identifier:
NCT00684944) [167] (Table 1). At 50 weeks, themean change
of ADAS-cog score of the 138mg/day dose group was better
than the mean change of patients initially receiving placebo
for 24 weeks and then 152mg/day for 26 weeks (2.8 and 5.2
points in mild and moderate patients, resp.). The most com-
monly reported adverse events (incidence ≥ 5%) in MTC-
treated subjects included gastrointestinal disorders (primar-
ily diarrhea), renal and urinary disorders (primarily dysuria
and frequency), and falls [166]. No changes of clinical signifi-
cance were observed in any routine clinical chemistry param-
eters in any treatment group. Treatment with MTC produced
dose-dependent decreases in red cell count and hemoglobin
and increases in methemoglobin. There were 4 cases (of 307
exposed to MTC) with methemoglobin greater than 3.5% (a
threshold set for withdrawal of treatment) which resolved
on cessation of treatment [166]. The authors of the study
reported that the delivery of the highest dose was impaired
due to dose-dependent dissolution and absorption factors
of the 100mg MTC gelatin capsule formulation [130]. At
present, MTC (Rember) was discontinued for AD treatment.
7. Pharmacokinetic, Preclinical, and
Clinical Studies with
Leucomethylthioninium and Derivatives
To the light of this functional and clinical dissociation identi-
fied forMT for AD treatment, TauRxTherapeutics developed
the synthesis of a novel chemical entity, TRx0237 (LMTX), a
second-generation TAI that is a stabilized, reduced form of
MTC, in which LMT is available in an anhydrous crystalline
form as the dihydromesylate or the dihydrobromide that is
stable in an oxygen atmosphere [131]. X-ray crystal structure
determinations of TRx0237 demonstrated that the nitrogen
atoms at positions 3 and 7 have tetrahedral geometry [131],
distinguishing it from LMT, in which the corresponding
nitrogen atoms are in a trigonal pyramidal geometry and not
protonated. Synthesis of LMT has to be performed under
an inert atmosphere because it rapidly oxidizes on exposure
to air, while TRx0237 can be manufactured in bulk without
the need for deoxygenation and remains stable for at least
2 years in air atmosphere. Thus, TRx0237 represents a new
chemical entity that is distinct from both MTC and LMT,
and it is highly soluble and exists as a single polymorph, in
contrast to MTC, which is far less soluble and demonstrates
heterogeneous polymorphism. TRx0237 remains stable for
at least 2 years in air atmosphere, is highly soluble, and
exists as a single polymorph [168]. An in vitro study showed
the ability of TRx 0237 in disrupting PHFs isolated from
AD brain tissues at the concentration at 0.16 𝜇M [131]. The
comparative in vivo pharmacological efficacy of MTC and
LMT salts (TRx0237: 5–75mg/kgwith oral administration for
3–8 weeks) was assessed in these two novel transgenic tau
mouse lines modeling cognitive and motor endophenotypes
of AD and FTLD tauopathies [169], namely, impairment in
spatial learning (L1) and motor learning (L66), respectively
[132]. In this in vivo study, both MTC and TRx0237 dose-
dependently rescued the learning impairment and restored
behavioral flexibility in a spatial problem-solving water maze
task in L1 (minimum effective dose: 35mgMT/kg for MTC,
9mgMT/kg for TRx0237) and corrected motor learning in
L66 (effective doses: 4mgMT/kg) [132]. Both compounds
reduced the number of tau-reactive neurons, particularly
in the hippocampus and entorhinal cortex in L1 and in a
more widespread manner in L66. The relative superiority
of TRx0237 compared with MTC appears to be therefore
more likely due to factors related to absorption, metabolism,
and distribution, rather than to inherent pharmacodynamic
differences.
No direct information on Phase I trials is available. A
4-week Phase II safety study of 250mg/day of TRx0237
in 9 patients with mild to moderate AD already taking
AChEIs and/or memantine began in September 2012 but
was terminated in April 2013, reportedly for administrative
reasons (ClinicalTrials.gov Identifier: NCT01626391) [170]
(Table 1). Currently, three Phase III trials with TRx0237 are
BioMed Research International 9
ongoing plus an open label extension study (Table 1).The first
study compares a single 200mg/day dose of the compound
to placebo in 700 patients with a diagnosis of either all-cause
dementia or AD mild enough to score above an MMSE of 20
(ClinicalTrials.gov Identifier: NCT01689233) [171] (Table 1).
Started in November 2012, this trial is ramping up to involve
more than 90 sites in North America and Europe, using as
primary outcome measures of efficacy the ADAS-Cog 11 and
the ADCS-CGIC scales. Temporal lobe brain metabolism is
measured by 18F-fluorodeoxyglucose- (FDG-) PET imaging
and safety parameters. The second Phase III trial compares
150 and 250mg/day of TRx0237 to placebo in 833 patients
with mild to moderate AD with an MMSE of 14 or higher
(ClinicalTrials.gov Identifier: NCT01689246) [172] (Table 1).
Begun in 2013, this trial is being conducted at more than
80 sites in North America, Australia, Europe, and Asia,
using clinical (ADCS-CGIC), cognitive (ADAS-Cog 11), and
safety measures as primary outcomes. The third Phase III
trial is evaluating TRx0237 (200mg/day) in 220 patients
affected by the behavioral variant of frontotemporal dementia
(bvFTD) and aMMSE above 20 (ClinicalTrials.gov Identifier:
NCT01626378) [173] (Table 1). This trial adopted a modified
version of the ADCS-CGIC scale as measure of clinical effi-
cacy and the revised Addenbrooke’s Cognitive Examination
as cognitive measure. This trial was started in August 2013
and will involve 45 sites in North America, Europe, Australia,
and Singapore. Finally, an open label extension study targets
providing subjects who have completed participation in a
Phase II or Phase III trials with TRx0237 continued access to
therapy and to evaluate the long-term safety of the compound
with an estimated study completion date of January 2017
(ClinicalTrials.gov Identifier: NCT02245568) [174] (Table 1).
All three Phase III trials use “active placebo” tablets that
include 4mg of TRx0237 as a urinary and fecal colorant
to help maintain blinding; therefore, the placebo group will
receive a total of 8mg/day of TRx0237. These Phase III trials
are now fully recruited and results from these ongoing studies
involving 250 centers in 22 countries around the world and
1,753 patients with mild to moderate AD or bvFTD are
expected in early 2016.
8. Conclusion
In the last two decades, drug discovery and development
efforts for AD research have been dominated by the “amyloid
cascade hypothesis,” focusing on targets defined by this
hypothesis andproposing amyloid as themain cause of neural
death and dementia. Decreasing the formation or removing
A𝛽 from the brain should attenuate dementia symptoms.
Unfortunately, several clinical trials with anti-A𝛽 agents
failed, challenging the hypothesis that A𝛽 accumulation is
the initiating event in the pathological AD cascade and
underscoring the need for novel therapeutic approaches and
targets. In recent years, tau-based treatments for AD have
become a point of increasing focus and current and previous
investigational therapies can be grouped into four categories
including tau-centric active and passive immunotherapies,
microtubule-stabilizing agents, tau protein kinase inhibitors,
andTAIs. Among these different approaches, smallmolecular
weight compounds developed to inhibit formation of tau
oligomers and fibrils by blocking tau-tau aggregation have
already reached the clinic. Among TAIs, MT belongs to a
class of diaminophenothiazines that have TAI activity in
vitro [97, 131]. MTC, in which MT is dosed as the oxidized
form MT+, was investigated in an exploratory Phase II dose-
ranging double-blind clinical trial in 321 patients with mild
to moderate AD [167]. The minimum effective dose was
identified as 138mgMT/day at both clinical and molecular
imaging endpoints at 24 weeks. Treatment at this dose was
found to prevent the decline in regional cerebral blood
flow, particularly in medial temporal lobe structures and
temporoparietal regions.
Given that the delivery of the highest dose of MT was
impaired due to dose-dependent dissolution and absorption
limitations, four Phase I studies [131] and two preclinical in
vitro [132] and in vivo studies [133] were required to get to the
bottom of the bioavailability limitations of the form of MT
tested in the Phase II trial [167], setting out the basis for pro-
ceeding into Phase III trials with TRx0237 for AD treatment.
Therefore, clinical development of MT for AD continues,
along with a new form that is more bioavailable and less
toxic at higher doses, called TRx0237, representing a new
chemical entity that is distinct from both MTC and LMT. A
broad-based approach to tau therapy appears favourable due
to the numerous pathologic mechanisms for tau pathology.
The potential contribution of tau conformation to inhibitory
potency of TAIs suggests a route toward selectivity and an
important target for future structural studies. In fact, iden-
tification of descriptors of inhibitory potency may provide a
rational approach to compound optimization [95].Therefore,
the therapeutic benefit that has been reported for MT in
Phase II stage and data from current Phase III trials will
allow us to glean on the larger scale impact of TRx0237 and
its therapeutic potential. However, the role of tau protein in
AD pathogenesis should be better understood with future
research including investigation of themechanisms/pathways
regulating the degradation of tau as determined by its post-
translational state, studies on soluble, nonaggregated forms
of tau as a primary AD agent, exploring the role of tau
as an enhancer of A𝛽-induced degeneration, and clarifying
the mechanisms by which pathological forms of tau may
negatively impact mitochondrial biology.
In this direction, the observation that acetylation of
soluble tau has important effects on the properties of
tau, including its stability and aggregation, and that tau
acetylation is elevated in patients at early and moderate
Braak stages of tauopathy [23] has opened new possibilities
of tau-based pharmacological approaches. A recent study
has proved that tau acetylated at lysine 174 is one of the
toxic species [175]. Increases in levels of this species have
been associated with toxicity and cognitive impairment in
transgenic mice. Conversely, blocking this acetylation with
salsalate, a nonsteroidal anti-inflammatory drug, preserved
cognition and led to improvements in pathology. Two to three
months of treatment preserved hippocampal volume and
reduced the number of NFTs by up to two-thirds. Moreover,
treated animals maintained their memories better than their
untreated littermates [175]. Because salsalate is an approved
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drug with a relatively good safety profile, it might be worth
testing in AD patients.
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“Protein folding andmechanisms of proteostasis,” International
Journal of Molecular Sciences, vol. 16, no. 8, pp. 17193–17230,
2015.
[37] S. M. Pritchard, P. J. Dolan, A. Vitkus, and G. V. W. Johnson,
“The toxicity of tau in Alzheimer disease: turnover, targets
and potential therapeutics,” Journal of Cellular and Molecular
Medicine, vol. 15, no. 8, pp. 1621–1635, 2011.
[38] B. Frost, R. L. Jacks, and M. I. Diamond, “Propagation of tau
misfolding from the outside to the inside of a cell,”The Journal
of Biological Chemistry, vol. 284, no. 19, pp. 12845–12852, 2009.
[39] F. Clavaguera, I. Lavenir, B. Falcon, S. Frank, M. Goedert, and
M. Tolnay, “Prion-like templated misfolding in tauopathies,”
Brain Pathology, vol. 23, no. 3, pp. 342–349, 2013.
[40] F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission
and spreading of tauopathy in transgenic mouse brain,” Nature
Cell Biology, vol. 11, no. 7, pp. 909–913, 2009.
[41] A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M.
Sigurdsson, “Immunotherapy targeting pathological tau con-
formers in a tangle mouse model reduces brain pathology with
associated functional improvements,” The Journal of Neuro-
science, vol. 27, no. 34, pp. 9115–9129, 2007.
[42] E. Masliah, E. Rockenstein, A. Adame et al., “Effects of 𝛼-synu-
clein immunization in a mouse model of Parkinson’s disease,”
Neuron, vol. 46, no. 6, pp. 857–868, 2005.
[43] P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte, and B. T.
Hyman, “Neurofibrillary tangles but not senile plaques parallel
duration and severity of Alzheimer’s disease,”Neurology, vol. 42,
no. 3, part 1, pp. 631–639, 1992.
[44] K. Iqbal, C.-X.Gong, andF. Liu, “Microtubule-associated protein
tau as a therapeutic target in Alzheimer’s disease,” Expert
Opinion onTherapeutic Targets, vol. 18, no. 3, pp. 307–318, 2014.
[45] J. T. Pedersen and E. M. Sigurdsson, “Tau immunotherapy for
Alzheimer’s disease,” Trends in Molecular Medicine, vol. 21, no.
6, pp. 394–402, 2015.
[46] K. Anand and M. Sabbagh, “Early investigational drugs target-
ing tau protein for the treatment of Alzheimer’s disease,” Expert
Opinion on Investigational Drugs, vol. 24, no. 10, pp. 1355–1360,
2015.
[47] S. Khatoon, I. Grundke-Iqbal, and K. Iqbal, “Brain levels of
microtubule-associated protein 𝜏 are elevated in Alzheimer’s
disease: a radioimmuno-slot-blot assay for nanograms of the
protein,” Journal of Neurochemistry, vol. 59, no. 2, pp. 750–753,
1992.
[48] L.Martin, X. Latypova, C.M.Wilson et al., “Tau protein kinases:
involvement in Alzheimer’s disease,” Ageing Research Reviews,
vol. 12, no. 1, pp. 289–309, 2013.
[49] C.-X. Gong and K. Iqbal, “Hyperphosphorylation of micro-
tubule-associated protein tau: a promising therapeutic target for
Alzheimer disease,”CurrentMedicinal Chemistry, vol. 15, no. 23,
pp. 2321–2328, 2008.
[50] F. Plattner, M. Angelo, and K. P. Giese, “The roles of cyclin-
dependent kinase 5 and glycogen synthase kinase 3 in tau
hyperphosphorylation,”The Journal of Biological Chemistry, vol.
281, no. 35, pp. 25457–25465, 2006.
[51] Y. Wen, E. Planel, M. Herman et al., “Interplay between cyclin-
dependent kinase 5 and glycogen synthase kinase 3𝛽 mediated
by neuregulin signaling leads to differential effects on tau
phosphorylation and amyloid precursor protein processing,”
Journal of Neuroscience, vol. 28, no. 10, pp. 2624–2632, 2008.
[52] R. V. Bhat, S. L. Budd Haeberlein, and J. Avila, “Glycogen
synthase kinase 3: a drug target for CNS therapies,” Journal of
Neurochemistry, vol. 89, no. 6, pp. 1313–1317, 2004.
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C. M. Pereira, “Pharmacological evidence that methylene blue
inhibits noradrenaline neuronal uptake in the rat vas deferens,”
Polish Journal of Pharmacology, vol. 55, no. 4, pp. 573–579, 2003.
[142] L. Vutskits, A. Briner, P. Klauser et al., “Adverse effects of
methylene blue on the central nervous system,” Anesthesiology,
vol. 108, no. 4, pp. 684–692, 2008.
[143] R. R. Ramsay, C. Dunford, and P. K. Gillman, “Methylene blue
and serotonin toxicity: inhibition of monoamine oxidase A
(MAO A) confirms a theoretical prediction,” British Journal of
Pharmacology, vol. 152, no. 6, pp. 946–951, 2007.
[144] M. Necula, L. Breydo, S. Milton et al., “Methylene blue inhibits
amyloid A𝛽 oligomerization by promoting fibrillization,” Bio-
chemistry, vol. 46, no. 30, pp. 8850–8860, 2007.
[145] D. X. Medina, A. Caccamo, and S. Oddo, “Methylene blue
reduces A𝛽 levels and rescues early cognitive deficit by increas-
ing proteasome activity,” Brain Pathology, vol. 21, no. 2, pp. 140–
149, 2011.
[146] S. Deiana, C. R. Harrington, C. M. Wischik, and G. Riedel,
“Methylthioninium chloride reverses cognitive deficits induced
by scopolamine: comparison with rivastigmine,” Psychophar-
macology, vol. 202, no. 1–3, pp. 53–65, 2009.
BioMed Research International 15
[147] P. D. Riha, J. C. Rojas, and F. Gonzalez-Lima, “Beneficial
network effects of methylene blue in an amnestic model,”
NeuroImage, vol. 54, no. 4, pp. 2623–2634, 2011.
[148] V. Paban, C. Manrique, M. Filali, S. Maunoir-Regimbal, F.
Fauvelle, and B. Alescio-Lautier, “Therapeutic and preventive
effects of methylene blue on Alzheimer’s disease pathology in a
transgenic mouse model,” Neuropharmacology, vol. 76, pp. 68–
79, 2014.
[149] T.Mori,N.Koyama, T. Segawa et al., “Methylene bluemodulates
𝛽-secretase, reverses cerebral amyloidosis, and improves cogni-
tion in transgenicmice,”The Journal of Biological Chemistry, vol.
289, no. 44, pp. 30303–30317, 2014.
[150] A. Zakaria, N. Hamdi, and R.M. Abdel-Kader, “Methylene blue
improves brain mitochondrial ABAD functions and decreases
A𝛽 in a neuroinflammatory Alzheimer’s disease mouse model,”
Molecular Neurobiology, vol. 53, no. 2, pp. 1220–1228, 2016.
[151] G. Roy Choudhury, A. Winters, R. M. Rich et al., “Methylene
blue protects astrocytes against glucose oxygen deprivation by
improving cellular respiration,” PLoS ONE, vol. 10, no. 4, Article
ID e0123096, 2015.
[152] Y. Wen, W. Li, E. C. Poteet et al., “Alternative mitochondrial
electron transfer as a novel strategy for neuroprotection,” The
Journal of Biological Chemistry, vol. 286, no. 18, pp. 16504–16515,
2011.
[153] E. Poteet, A. Winters, L.-J. Yan et al., “Neuroprotective actions
of methylene blue and its derivatives,” PLoS ONE, vol. 7, no. 10,
article e48279, 2012.
[154] C. Stack, S. Jainuddin, C. Elipenahli et al., “Methylene blue
upregulates Nrf2/ARE genes and prevents tau-related neuro-
toxicity,” Human Molecular Genetics, vol. 23, no. 14, Article ID
ddu080, pp. 3716–3732, 2014.
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